UNICHEM LABORATORIES LTD.
NSE : UNICHEMLABBSE : 506690ISIN
CODE : INE351A01035Industry : Pharmaceuticals & DrugsHouse
: Private
BSE561.401.2 (+0.21 % )
PREV CLOSE (Rs.) 560.20
OPEN PRICE (Rs.) 555.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3287
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE560.05 1.7 (+0.3 % )
PREV CLOSE(Rs.) 558.35
OPEN PRICE (Rs.) 555.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 20860
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 26-Mar-2024 | Unichem Laboratories informs about closure of trading window | <div style="text-align: justify;">Unichem Laboratories has informed that pursuant to the Company's code of conduct to Regulate, Conduct, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as duly amended, the Trading Window for dealing in shares of the Company will be closed from April 1, 2024 and shall open 48 hours after the financial results for the quarter and year ended March 31, 2024 are made public.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 23-Mar-2024 | Unichem Laboratories informs about results of postal ballot and scrutinizer's report | <p style="text-align: justify;">Pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unichem Laboratories has informed that it enclosed the result of remote e-voting in the prescribed format along with Scrutinizer's consolidated report for the below resolutions which were proposed for the approval of the Members through Postal Ballot. a. Appointment of Anand Kusre (DIN 00818477) as a Non-Executive Independent Director for a term of five years with effect from 5th February 2024, b. Appointment of Arun Todarwal (DIN 00020916) as a Non-Executive Independent Director for a term of five years with effect from 5th February 2024, c. Material related party transaction(s) with Ipca Laboratories (‘Ipca'), holding company of Unichem Laboratories, d. Material related party transaction(s) between Ipca, holding company of Unichem and Unichem Pharmaceuticals USA Inc. (‘Unichem USA'), wholly owned subsidiary of Unichem, e. Material related party transaction(s) with Unichem USA, wholly owned subsidiary of Unichem. The resolutions as proposed in the postal ballot notice have been passed by the shareholders by remote e-voting process with requisite majority and are deemed to be passed on the last date of the remote e-voting period i.e. Friday, 22nd March 2024. The said results and the scrutinizer's report will be available on the Company's website: www.unichemlabs.com and that of the exchanges namely www.bseindia.com and www.nseindia.com and the website of the e-voting agency: www.evotingindia.com.</p><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 22-Feb-2024 | Unichem Laboratories informs about press release | <div>Unichem Laboratories has informed that it enclosed the publication dated February 22, 2024, in newspapers namely Business Standard and Mumbai Lakshdeep regarding the Notice of Postal Ballot and eVoting pursuant to Section 110 of the Companies Act, 2013 and the Rules made thereunder.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 21-Feb-2024 | Unichem Laboratories informs about postal ballot notice | <p style="text-align: justify;">Unichem Laboratories has informed that it enclosed the Postal Ballot Notice together with the explanatory statement seeking the approval of the members of the Company on the following Special Business items as set out in the Notice dated 5th February, 2024: 1. Special resolution for approval of appointment of Anand Kusre (DIN 00818477) as a Non-Executive Independent Director for a term of five years with effect from 5th February, 2024. 2. Special resolution for approval of appointment of Arun Todarwal (DIN 00020916) as a Non-Executive Independent Director for a term of five years with effect from 5th February, 2024. 3. Ordinary resolution for approval of material related party transaction(s) with Ipca Laboratories (‘Ipca'), holding company of Unichem Laboratories (‘Unichem'). 4. Ordinary resolution for approval of material related party transaction(s) between Ipca, holding company of Unichem and Unichem Pharmaceuticals USA Inc. (‘Unichem USA'), wholly owned subsidiary of Unichem. 5. Ordinary resolution for approval of material related party transaction(s) with Unichem USA, wholly owned subsidiary of Unichem. Notice is being sent through electronic mode to those members whose e-mail addresses are registered with the Company/Depositories and whose names are recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories as on Friday, 16th February, 2024. The notice is being sent by e-mail on 21st February, 2024 to the members who have registered their e-mail IDs with Depository Participant(s) or with the Company. E-voting period will commence from Thursday, 22nd February, 2024, IST at 9.00 am and will end on Friday, 22nd March, 2024 IST at 5.00 pm. The Notice will also be available on the website of the Company at www.unichemlabs.com and on the website of the Central Depository Services (India) (CDSL) at https://www.evotingindia.com/.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div><br></div> |
| 21-Feb-2024 | Appointment of Director | Inter alia, considered and approved:- Based on the recommendations of Nomination & Remuneration Committee meeting, Board has also approved the appointment of Mr. Anand Kusre (DIN 00818477) and Mr. Arun Todarwal (DIN 00020916) as Independent Directors of the Company for a term of five consecutive years with effect from February 5, 2024. |
| 11-Jan-2024 | Unichem Laboratories gets ANDA approval for Doxazosin tablets | <p style="text-align: justify;">Unichem Laboratories has received ANDA approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC. </p><p style="text-align: justify;">Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem's Goa Plant. </p><p style="text-align: justify;">Unichem Laboratories is an international, integrated, specialty pharmaceutical company.</p> |
| 11-Jan-2024 | Unichem Laboratories soars on getting ANDA approval for Doxazosin tablets | <p style="text-align: justify;">Unichem Laboratories is currently trading at Rs. 466.80, up by 21.30 points or 4.78% from its previous closing of Rs. 445.50 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 436.60 and has touched a high and low of Rs. 479.25 and Rs. 436.60 respectively. So far 4642 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 479.25 on 11-Jan-2024 and a 52 week low of Rs. 265.00 on 25-Jan-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 479.25 and Rs. 436.60 respectively. The current market cap of the company is Rs. 3286.54 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 70.22%, while Institutions and Non-Institutions held 11.31% and 18.47% respectively.</p><p style="text-align: justify;">Unichem Laboratories has received ANDA approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC. </p><p style="text-align: justify;">Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem's Goa Plant. </p><p style="text-align: justify;">Unichem Laboratories is an international, integrated, specialty pharmaceutical company. </p> |
| 09-Jan-2024 | Unichem Laboratories informs about certificate | <p style="text-align: justify;">Unichem Laboratories has informed that it enclosed a certificate dated January 5, 2024 issued by Link Intime India, Registrar & Share Transfer Agent of Company confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2023.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 05-Dec-2023 | Unichem Laboratories sells balance stake in Optimus Drugs | <p style="text-align: justify;">Unichem Laboratories has sold balance 4918 equity shares representing 0.02% holding in Optimus Drugs to Sekhmet Pharmaventures for an aggregate consideration of Rs 67.47 crore. In May 2022, the company sold 19.97% of equity shares of Optimus to Sekhmet Pharmaventures on a fully diluted basis in the first tranche, for an aggregate consideration of Rs 270.99 crore.</p><p style="text-align: justify;">Unichem Laboratories is an international, integrated, specialty pharmaceutical company.</p> |
| 30-Aug-2023 | Unichem Laboratories gets ANDA approval for Prasugrel Tablets | <p style="text-align: justify;">Unichem Laboratories has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.</p><p style="text-align: justify;">Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem's Goa Plant.</p><p style="text-align: justify;">Unichem Laboratories is an international, integrated, specialty pharmaceutical company.</p> |
